BOSTON SCIENTIFIC CORP (BSX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does BOSTON SCIENTIFIC CORP Do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts. BOSTON SCIENTIFIC CORP (BSX) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Michael F. Mahoney and employs approximately 45,000 people, headquartered in Marlborough, Massachusetts. With a market capitalization of $92.1B, BSX is one of the prominent companies in the Healthcare sector.
BOSTON SCIENTIFIC CORP (BSX) Stock Rating — Reduce (April 2026)
As of April 2026, BOSTON SCIENTIFIC CORP receives a Reduce rating with a composite score of 41.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.BSX ranks #2,600 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BOSTON SCIENTIFIC CORP ranks #339 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
BSX Stock Price and 52-Week Range
BOSTON SCIENTIFIC CORP (BSX) currently trades at $61.69. The stock gained $0.41 (0.7%) in the most recent trading session. The 52-week high for BSX is $109.50, which means the stock is currently trading -43.7% from its annual peak. The 52-week low is $67.56, putting the stock -8.7% above its annual trough. Recent trading volume was 14.8M shares, indicating strong institutional interest and high liquidity.
Is BSX Overvalued or Undervalued? — Valuation Analysis
BOSTON SCIENTIFIC CORP (BSX) carries a value factor score of 56/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 34.18x, compared to the Healthcare sector average of 23.63x — a premium of 45%. The price-to-book ratio stands at 3.76x, versus the sector average of 2.75x. The price-to-sales ratio is 4.84x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, BSX trades at 26.11x EV/EBITDA, versus 6.34x for the sector.
Overall, BSX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
BOSTON SCIENTIFIC CORP Profitability — ROE, Margins, and Quality Score
BOSTON SCIENTIFIC CORP (BSX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 11.0%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 6.2% versus the sector average of -33.1%.
On a margin basis, BOSTON SCIENTIFIC CORP reports gross margins of 68.8%, compared to 71.5% for the sector. The operating margin is 18.5% (sector: -66.1%). Net profit margin stands at 14.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 22.9% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
BSX Debt, Balance Sheet, and Financial Health
BOSTON SCIENTIFIC CORP has a debt-to-equity ratio of 78.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.62x, suggesting adequate working capital coverage. Total debt on the balance sheet is $11.60B. Cash and equivalents stand at $1.27B.
BSX has a beta of 0.58, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for BOSTON SCIENTIFIC CORP is 67/100, reflecting average volatility within the normal range for its sector.
BOSTON SCIENTIFIC CORP Revenue and Earnings History — Quarterly Trend
In TTM 2026, BOSTON SCIENTIFIC CORP reported revenue of $19.00B and earnings per share (EPS) of $1.96. Net income for the quarter was $2.69B. Gross margin was 68.8%. Operating income came in at $3.52B.
In FY 2025, BOSTON SCIENTIFIC CORP reported revenue of $20.07B and earnings per share (EPS) of $1.96. Net income for the quarter was $2.89B. Gross margin was 69.0%. Revenue grew 19.9% year-over-year compared to FY 2024. Operating income came in at $3.61B.
In Q3 2025, BOSTON SCIENTIFIC CORP reported revenue of $5.07B and earnings per share (EPS) of $0.51. Net income for the quarter was $755M. Gross margin was 69.9%. Revenue grew 20.3% year-over-year compared to Q3 2024. Operating income came in at $1.05B.
In Q2 2025, BOSTON SCIENTIFIC CORP reported revenue of $5.06B and earnings per share (EPS) of $0.54. Net income for the quarter was $795M. Gross margin was 67.7%. Revenue grew 22.8% year-over-year compared to Q2 2024. Operating income came in at $819M.
Over the past 8 quarters, BOSTON SCIENTIFIC CORP has demonstrated a growth trajectory, with revenue expanding from $4.12B to $19.00B. Investors analyzing BSX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
BSX Dividend Yield and Income Analysis
BOSTON SCIENTIFIC CORP (BSX) does not currently pay a dividend. This is common among growth-oriented companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
BSX Momentum and Technical Analysis Profile
BOSTON SCIENTIFIC CORP (BSX) has a momentum factor score of 21/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 31/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
BSX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, BOSTON SCIENTIFIC CORP (BSX) ranks #339 out of 838 stocks based on the Blank Capital composite score. This places BSX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing BSX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BSX vs S&P 500 (SPY) comparison to assess how BOSTON SCIENTIFIC CORP stacks up against the broader market across all factor dimensions.
BSX Next Earnings Date
No upcoming earnings date has been announced for BOSTON SCIENTIFIC CORP (BSX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy BSX? — Investment Thesis Summary
The quantitative profile for BOSTON SCIENTIFIC CORP suggests caution. Momentum is weak at 21/100, a headwind for near-term performance. Low volatility (stability score 67/100) reduces downside risk.
In summary, BOSTON SCIENTIFIC CORP (BSX) earns a Reduce rating with a composite score of 41.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BSX stock.
Related Resources for BSX Investors
Explore more research and tools: BSX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BSX head-to-head with peers: BSX vs AZN, BSX vs SLGL, BSX vs VMD.